We recently published a list of the 12 Most Oversold Healthcare Stocks to Buy Now. In this article, we are going to take a ...

Baron Funds, an investment management company, released its “Baron Health Care Fund” fourth quarter 2024 investor letter. The ...

Bristol-Myers Squibb's has become the first company to bring a cardiac myosin inhibitor through to FDA approval, claiming a green light from the US regulator for mavacamten as a therapy for ...

Cytokinetics is readying for potential regulatory approvals and commercialization of aficamten, a potential next-in-class cardiac myosin inhibitor following positive results from SEQUOIA-HCM ...

Cytokinetics has said that the broad efficacy and encouraging safety profile of aficamten give it a chance of becoming the “cardiac myosin inhibitor of choice among physicians and patients.” ...

Aficamten is a next-in-class cardiac myosin inhibitor for the potential treatment of patients with HCM. In 2020, CORXEL (formerly Ji Xing) acq Key Insights Using the 2 Stage Free Cash Flow to ...

In frame translation initiation sites within coding sequences drive the expression of N-terminally truncated proteoforms.

Cardiomyopathies are diseases of the heart muscle. This group of pathological conditions includes dilated cardiomyopathy, hypertrophic cardiomyopathy, restrictive cardiomyopathy, arrhythmogenic ...

The common presenting symptoms among individuals with HCM include dyspnea, angina, and presyncope or syncope. Chest pain may occur at rest or be precipitated by exertion or, among those with LVOTO ...

Hypertrophic cardiomyopathy (HCM) is an uncommon disease with significant consequences. Since the 1950s, major strides in understanding its etiology and pathogenesis have led to improved ...